论文部分内容阅读
目的探究使用益生菌联合美沙拉嗪治疗炎症性肠病的临床治疗效果。方法 42例炎症性肠病患者,随机分为观察组和对照组,各21例。对照组患者使用美沙拉嗪进行治疗,观察组患者在对照组治疗基础上给予益生菌进行治疗。观察并比较2个月后两组患者的临床治疗效果和不良反应发生情况。结果观察组的治疗总有效率为90.48%,明显优于对照组的57.14%(P<0.05);观察组肠镜复查总有效率为95.24%,不良反应发生率为9.53%,对照组肠镜复查总有效率为71.43%,不良反应发生率为33.33%,两组比较差异均具有统计学意义(P<0.05)。结论使用益生菌联合美沙拉嗪治疗炎症性肠病可以取得良好的疗效,并且安全性比较高,值得临床推广。
Objective To investigate the clinical efficacy of probiotics combined with mesalazine in the treatment of inflammatory bowel disease. Methods Forty-two patients with inflammatory bowel disease were randomly divided into observation group and control group, with 21 cases in each group. Patients in the control group were treated with mesalazine. Patients in the observation group were treated with probiotics on the basis of the control group. Observed and compared two months after the two groups of patients with clinical treatment and adverse reactions. Results The total effective rate of the observation group was 90.48%, which was significantly better than that of the control group (57.14%, P <0.05). The total effective rate of the colonoscopy in the observation group was 95.24% and the incidence of adverse reactions was 9.53% The total effective rate of review was 71.43% and the incidence of adverse reactions was 33.33%. The differences between the two groups were statistically significant (P <0.05). Conclusion Probiotics combined with mesalazine in the treatment of inflammatory bowel disease can achieve good results, and the safety is relatively high, worthy of clinical promotion.